Navigation Links
IceCure Enters a New High-Potential Market: The company received $100K-order for cryoablation consoles and probes to be used in a clinical study for the treatment of lung cancer

CAESAREA, Israel and CLEVELAND, Oct. 1, 2013 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) announced today that it received its first order for cryoablation systems to be used in a clinical study for treatment of lung cancer tumors. The study will take place at the Kameda Medical Center in Kamogawa City, Japan. The cryoablation systems and probes are based on IceSense3™ technology.  Currently the IceSense3™ system is being studied in the same center for the treatment of small breast cancer tumors.

(Photo: )

Cryoablation is the technique of using extreme cold to destroy tissue.  It has been used for years in medical applications such as dermatology, kidney, prostate and liver to treat both cancerous and non-cancerous tumors.

"This study, which is fully funded by Kameda Medical Center, may pave the road for IceCure to also use its cryoablation systems for the treatment of lung cancer tumors in addition to the current commercial applications for the treatment of benign breast tumors and investigational use for small breast cancers," stated Hezi Himelfarb, President and CEO of IceCure Medical.  "According to the American Cancer Society, lung cancer is the leading cancer killer of both men and women in the United States, more than the next three cancers combined (colon, breast and prostate). An estimated 160,340 Americans were expected to die from lung cancer in 2012, accounting for approximately 28 percent of all cancer deaths."

"It is important to mention that an animal study conducted last July using IceCure's system, has shown better results when compared with other cryoablation systems. Successful results in the Japanese trial may open the possibility to enter a huge market with hundreds of thousands of new cases every year. We continue our marketing and sales efforts in the U.S. for the treatment of (benign) breast fibroadenoma, as well as the clinical studies for treating breast cancer tumors in Japan and the U.S," added Himelfarb.

The clinical study will be managed by Dr. Akihiko Takeshi, the chairman of the Thoracic Surgery Department at Kameda Medical Center and will be funded by the hospital. After analyzing the results, the company will decide its future involvement in the treatment of lung cancer tumors using its cryoablation technology.

Eisuke Fukuma, MD, PhD, Chairman of Breast Center at Kameda Medical Center in Kamogawa City, Japan has been developing cryoablation under image-guidance as a nonsurgical treatment for small breast cancer since 2006. Dr. Fukuma's most recent 20 patients added to the clinical trial were treated using IceCure Medical's IceSense3™ cryoablation system.

While mainstream cancer treatment still requires significant research, the IceSense3 system is widely available in the U.S. for the treatment of benign breast disease.  The procedure usually takes about 10-15 minutes, with no pain and virtually no scar (no sutures are required). As with a needle biopsy, many women can return to work or their normal activity quickly.

The IceSense3™ Cryoablation System was designed for efficient and effective treatment of breast tumors. The system has 510k FDA-approval for benign and malignant breast disease.

About IceCure Medical

IceCure Medical, is a medical device company focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's health. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. The company was founded in 2006 with main offices in Caesarea, Israel and U.S. headquarters in Cleveland, Ohio. For more information, visit  

For more information, contact
Will Irby
IceCure Medical, Inc.
(901) 237-4630

SOURCE IceCure Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
3. CyberKnife System and the da Vinci Surgical System in Concord Medical Centers Achieve Over RMB 10 Million in Medical Revenue Since Opening in February
4. 3 Pediatric Centers that Offer SynCardia Total Artificial Heart Named in Top 10 for "Best Childrens Hospitals"
5. Abaxis Enters Into Definitive Agreement To Deliver 300 Piccolo Xpress Instruments For A Four-Year Drug Clinical Trial
6. The Galien Foundation Announces Roster of Luminary Presenters for Third Galien Forum; Program Highlights Include CEO Panel, Panel on Alzheimers Disease Innovation, Nobel Laureate Elie Wiesel
7. ApolloMed ACO Selected To Participate In A Transformative New Initiative Sponsored by the Centers for Medicare and Medicaid Services
8. Spine Pain Management Opens Two Additional Affiliate Diagnostic Centers in Florida
9. Caspase Inhibitor Enters Clinical Trial In Islet Transplantation As Treatment For Diabetes
10. CVS Caremark Charitable Trust Partners with National Association of Community Health Centers to Create Innovative Grant Program Focused on Managing Chronic Disease
11. Winner Medical Enters into Definitive Merger Agreement with Winner Holding Limited
Post Your Comments:
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... authorized OSHA Training Institute Education Center headquartered in Northern California, has issued an ... extreme heat at their worksites. Employers with workers exposed to high temperatures ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... TherapySites, ... its affiliation with Tennessee Counseling Association. This new relationship allows TherapySites ... Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA is extremely ...
(Date:6/27/2016)... California (PRWEB) , ... June ... ... pioneer in the patient payment industry today announced its strategic partnership with ... health system workflows. , The two companies’ proven, proprietary technology combine to ...
(Date:6/27/2016)... ... June 27, 2016 , ... A ... revolutionize the emergency ambulance transport experience for the millions of people who require ... has disrupted the taxi industry through the use of technology. Now, SmartEMS has ...
Breaking Medicine News(10 mins):